f-627
Breast Cancer
EVIVE BiotechnologyPhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 72/ 100
- Competitive Position
- 59/ 100
Competitive context
891 Active assets in the Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Darolutamide Vandana Abramson | Phase 2 | BBB |
Palbociclib Hoffmann-La Roche | Phase 4 | BB |
Ribociclib National Cancer Institute (NCI) | Phase 4 | BB |
Trastuzumab Duocarmazine Byondis B.V. | Phase 3 | BB |
ERIBULIN MONOMETHANESULFONATE Henan Cancer Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
f-627 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →